Active Ingredient: Maraviroc
Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adults, adolescents and children of 2 years of age, and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral
150 - 600
From 75 To 300 2 time(s) per day every day
The recommended dose of maraviroc is 150 mg (with potent CYP3A inhibitor with or without a potent CYP3A inducer), 300 mg (without potent CYP3A inhibitors or inducers) or 600 mg twice daily (with potent CYP3A inducer without a potent CYP3A inhibitor) depending on interactions with concomitant antiretroviral therapy and other medicinal products.
There is limited experience in patients >65 years of age, therefore maraviroc should be used with caution in this population.
For:
Oral
50 - 300
From 25 To 150 2 time(s) per day every day
The recommended dose of maraviroc should be based on body weight (kg) and should not exceed the recommended adult dose.
The recommended dose of maraviroc differs depending on interactions with concomitant antiretroviral therapy and other medicinal products.
Many medicines have profound effects on maraviroc exposure due to drug-drug interactions. Prior to deciding the dose of maraviroc by weight, please refer to interactions and adult dose recommendations with other medicinal products to carefully determine the corresponding adult dose. The corresponding paediatric dose can then be obtained from the table below. If uncertainty still exists, contact a pharmacist for advice.
Recommended dosing regimen in children aged 2 years and above and weighing at least 10 kg:
| Adult dosage* | Concomitant Medications | Dose of maraviroc in children based on weight | |||
| 10 to less than 20 kg | 20 to less than 30 kg | 30 to less than 40 kg | at least 40 kg | ||
| 150 mg twice daily | Maraviroc with products that are potent CYP3A inhibitors (with or without a CYP3A inducer) | 50 mg twice daily | 75 mg twice daily | 100 mg twice daily | 150 mg twice daily |
| 300 mg twice daily | Maraviroc with products that are not potent CYP3A inhibitors or potent CYP3A inducers | Data to support these doses are lacking. | 300 mg twice daily | 300 mg twice daily | |
| 600 mg twice daily | Maraviroc with products that are CYP3A inducers (without a potent CYP3A inhibitor) | Data to support these doses are lacking and maraviroc is not recommended in children taking concomitant interacting medicinal products that in adults would require a 600 mg twice daily dose. | |||
* Based on drug-drug interactions
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.